Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Otorhinolaryngology

Free Subscription Articles published in Radiother Oncol Retrieve available abstracts of 212 articles: HTML format

Single Articles

September 2026
1. CHEN X, Huang Y, Lin K, Chen J, et al
   De-escalating elective nodal irradiation dose to 45?Gy in nasopharyngeal carcinoma: A large-cohort study with 5-year outcomes.
   Radiother Oncol. 2026 Sep 25:111795. doi: 10.1016/j.radonc.2026.111795.
   PubMed     Abstract available
   
   
   
2. VAN KEEKEN K, Badiu V, Vilches-Freixas G, Buijsen J, et al
   Impact of accumulated target dose on tumor response in distal esophageal cancer treated with intensity-modulated proton therapy.
   Radiother Oncol. 2026;225:111788.
   PubMed     Abstract available
   
   
   
3. CANTERS R, Badiu V, Reijtenbagh D, Kneepkens E, et al
   Corrigendum to "Temporal heart dose variations during IMPT for esophageal cancer and the impact of an adaptation protocol" [Radiother. Oncol. 223 (2026) 111717].
   Radiother Oncol. 2026;224:111773.
   PubMed    
   
   
   
4. HUANG R, Lou J, Li C, Xu Z, et al
   Risk and prognostic survival analysis of radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma: intensity-modulated radiotherapy and two-dimensional radiotherapy.
   Radiother Oncol. 2026 Sep 13:111776. doi: 10.1016/j.radonc.2026.111776.
   PubMed     Abstract available
   
   
   
5. RUHLE A, Sanz-Garcia E, Su J, O'Sullivan B, et al
   Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.
   Radiother Oncol. 2026 Sep 4:111769. doi: 10.1016/j.radonc.2026.111769.
   PubMed     Abstract available
   
   
   
6. KAUFMANN J, Nikolaidou E, Krabbes I, Oji N, et al
   Medial retropharyngeal lymph node involvement in nasopharyngeal cancer patients treated with radiotherapy in Germany - A multicenter analysis.
   Radiother Oncol. 2026;222:111696.
   PubMed     Abstract available
   
   
   
7. CHATTERJEE S, Maulik S, Sharma J, Khanum H, et al
   Results of intensifying radiation treatment in advanced laryngeal, hypopharyngeal (LH) and oropharyngeal cancers (OPC) using metabolic dose escalation strategies: (INTELHOPE).
   Radiother Oncol. 2026;222:111698.
   PubMed     Abstract available
   
   
   
8. NAKAMURA S, Kodaira T, Machida R, Nakashima T, et al
   Definitive IMRT alone with reduced prophylactic nodal irradiation for Early-Stage Oropharyngeal Cancer: JCOG1208.
   Radiother Oncol. 2026;222:111677.
   PubMed     Abstract available
   
   
   
9. PARK SG, Yang E, Nam H, Kim TG, et al
   Tumor volume reduction during adaptive radiotherapy is a strong prognostic factor for oropharyngeal cancer: A retrospective multicenter study.
   Radiother Oncol. 2026;222:111676.
   PubMed     Abstract available
   
   
   
10. CACICEDO J, Hoyo OD, Canon V
    GTV Expert Opinion: Pushing the limits in re-irradiation in head and neck cancer: challenges, strategies and safety.
    Radiother Oncol. 2026;222:111581.
    PubMed    
    
    
    August 2026
11. HE Q, Li Y, Long J, Luo X, et al
    Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled phase III clinical trial.
    Radiother Oncol. 2026;223:111746.
    PubMed     Abstract available
    
    
    
12. CANTERS R, Badiu V, Reijtenbagh D, Kneepkens E, et al
    Temporal heart dose variations during IMPT for esophageal cancer and the impact of an adaptation protocol.
    Radiother Oncol. 2026 Aug 4:111717. doi: 10.1016/j.radonc.2026.111717.
    PubMed     Abstract available
    
    
    
13. LI Z, Yang Y, Yin X, Zheng C, et al
    Single-cell and spatial transcriptomics delineate the remodeling of esophageal squamous-cell carcinoma ecosystem following diverse therapies.
    Radiother Oncol. 2026 Aug 4:111720. doi: 10.1016/j.radonc.2026.111720.
    PubMed     Abstract available
    
    
    
14. BELTZUNG F, Biau J, Pereira B, Saroul N, et al
    Tumor immune microenvironment predicts recurrence after radiotherapy in oropharyngeal squamous cell carcinoma.
    Radiother Oncol. 2026;221:111620.
    PubMed     Abstract available
    
    
    
15. HSU C, Ku HL, Lin SM, Lee HL, et al
    Multicenter validation and randomized crossover reader evaluation of deep learning-assisted tri-sequence three-dimensional MRI segmentation for hypopharyngeal tumor.
    Radiother Oncol. 2026;221:111606.
    PubMed     Abstract available
    
    
    
16. HARALDSSON A, Askmyr D, Altunbulakli C, Nilsson M, et al
    Artificial intelligence classification of spatial CD8 + T-cell distribution on computed tomography in oropharyngeal cancer.
    Radiother Oncol. 2026;221:111607.
    PubMed     Abstract available
    
    
    July 2026
17. YANG Q, Fang J, Chen C, Zhang C, et al
    The TFDP2-PDK3 axis drives glucose metabolic reprogramming to promote radioresistance in nasopharyngeal carcinoma.
    Radiother Oncol. 2026 Jul 28:111708. doi: 10.1016/j.radonc.2026.111708.
    PubMed     Abstract available
    
    
    
18. BECHERINI C, Banini M, Blanchard P, Brana I, et al
    Integration of radiation therapy with systemic treatments in head and neck cancer: expert opinion and roadmap to consensus.
    Radiother Oncol. 2026;223:111711.
    PubMed     Abstract available
    
    
    
19. DEN BOER RB, Mook S, van Laarhoven HWM, Voncken FEM, et al
    Response prediction after neoadjuvant chemoradiotherapy in esophageal cancer using FDG-PET and multiparametric MRI: A prospective multicenter study.
    Radiother Oncol. 2026 Jul 10:111687. doi: 10.1016/j.radonc.2026.111687.
    PubMed     Abstract available
    
    
    
20. PENG Y, Chen S, Qin A, Chen M, et al
    Corrigendum to "Magnetic resonance-based synthetic computed tomography images generated using generative adversarial networks for nasopharyngeal carcinoma radiotherapy treatment planning" [Radiother. Oncol. 150 (2020) 217-224].
    Radiother Oncol. 2026;222:111609.
    PubMed    
    
    
    June 2026
21. LOOMAN EL, van Zon-Meijer TWH, Ludwig R, Perez Haas Y, et al
    Patterns of lymphatic spread in laryngeal squamous cell carcinoma and personalization of the elective clinical target volume.
    Radiother Oncol. 2026;219:111491.
    PubMed     Abstract available
    
    
    May 2026
22. YANG SS, Zhao YN, He Y, Liu YB, et al
    Deep learning for detection and automatic visualization of radiation-induced temporal lobe injury in nasopharyngeal carcinoma across endemic and non-endemic areas in China.
    Radiother Oncol. 2026 May 13:111596. doi: 10.1016/j.radonc.2026.111596.
    PubMed     Abstract available
    
    
    April 2026
23. WANG C, Wang W, Zong D, Ding M, et al
    Capturing "source" and "evolution": A 5-year recurrence risk prediction model for nasopharyngeal carcinoma based on integrated radiomic spatial heterogeneity of primary tumor and lymph nodes.
    Radiother Oncol. 2026 Apr 28:111552. doi: 10.1016/j.radonc.2026.111552.
    PubMed     Abstract available
    
    
    
24. WISHART LR, O'Shea J, Rischin D, Corry J, et al
    Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT).
    Radiother Oncol. 2026 Apr 23:111550. doi: 10.1016/j.radonc.2026.111550.
    PubMed     Abstract available
    
    
    
25. YAN Z, Chen J, Zhu J, Lin K, et al
    Individualized risk-adapted cranial border for nodal clinical target volume in nasopharyngeal carcinoma: challenging the universal skull base rule.
    Radiother Oncol. 2026 Apr 12:111534. doi: 10.1016/j.radonc.2026.111534.
    PubMed     Abstract available
    
    
    
26. YE W, Zhang M, Gong M, Lyu X, et al
    Effects of rhuGM-CSF on prevention and treatment of oral mucositis in patients receiving radiotherapy for head and neck cancer: A randomized controlled trial.
    Radiother Oncol. 2026;219:111527.
    PubMed     Abstract available
    
    
    
27. CARTECHINI G, Schnelzauer L, Cordoni FG, Liu S, et al
    Proton-specific dose and radiation quality constraints to reduce acute oral mucositis in head and neck cancer patients.
    Radiother Oncol. 2026 Apr 5:111522. doi: 10.1016/j.radonc.2026.111522.
    PubMed     Abstract available
    
    
    March 2026
28. EIDE HA, Grut H, Jebsen P, Kyte JA, et al
    Hyperfractionated reirradiation and PD-1 blockade in recurrent squamous cell head and neck carcinomas with poor prognosis, results from the REPORT-trial.
    Radiother Oncol. 2026 Mar 29:111514. doi: 10.1016/j.radonc.2026.111514.
    PubMed     Abstract available
    
    
    
29. POINTREAU Y, Larnaudie A, Sun XS, Rolland F, et al
    Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.
    Radiother Oncol. 2026;219:111479.
    PubMed     Abstract available
    
    
    
30. NIMURA K, Noguchi M, Koide Y
    Optimizing chemoradiotherapy for elderly esophageal cancer: The need for CGA-based stratification and statistical robustness.
    Radiother Oncol. 2026 Mar 22:111498. doi: 10.1016/j.radonc.2026.111498.
    PubMed    
    
    
    
31. AMERI A, Lesan M, Vafaei V, Taghizadeh-Hesary F, et al
    Therapeutic effect of Photobiomodulation therapy on radiation-induced oral mucositis in head and neck Cancer: A prospective double-blind, self-controlled clinical trial.
    Radiother Oncol. 2026;219:111495.
    PubMed     Abstract available
    
    
    
32. MACRAE DC, van der Hoek L, de Vette SPM, Neh H, et al
    A multi-toxicity deep learning approach for normal tissue complication probability modelling in head and neck cancer patients receiving radiotherapy.
    Radiother Oncol. 2026 Mar 17:111486. doi: 10.1016/j.radonc.2026.111486.
    PubMed     Abstract available
    
    
    
33. RAO M, Liao J, Li X, Long L, et al
    Oscillatory and recurrent drivers of symptom networks in head and neck cancer radiotherapy: a longitudinal cross-lagged panel network study.
    Radiother Oncol. 2026 Mar 17:111487. doi: 10.1016/j.radonc.2026.111487.
    PubMed     Abstract available
    
    
    
34. LARROTTA-CASTILLO D, Chen YH, van der Hoek L, Ramaekers B, et al
    Post-radiotherapy health utility and symptom trends in patients with non-metastatic head and neck cancer.
    Radiother Oncol. 2026 Mar 9:111473. doi: 10.1016/j.radonc.2026.111473.
    PubMed     Abstract available
    
    
    
35. ADRIAN G, Falklind NR, McDowell L, Gebre-Medhin M, et al
    Six versus five fractions per week (Chemo)-Radiotherapy for locally advanced head and neck squamous cell carcinoma - A nationwide cohort study from the swedish head and neck cancer register.
    Radiother Oncol. 2026 Mar 7:111481. doi: 10.1016/j.radonc.2026.111481.
    PubMed     Abstract available
    
    
    
36. GONG J, Yang Z, Li J, Wang Q, et al
    A longitudinal CT-based subregional radiomics nomogram for predicting local recurrence-free survival in esophageal squamous cell carcinoma after definitive chemoradiotherapy: a multicenter study.
    Radiother Oncol. 2026;218:111471.
    PubMed     Abstract available
    
    
    
37. ELSHARIEF MM, Hassouna AH, Shouman T, Mosallam A, et al
    Single vocal cord irradiation (SVCI) vs whole laryngeal radiotherapy in the treatment of T1aN0 glottic cancer A prospective randomized trial.
    Radiother Oncol. 2026;216:111376.
    PubMed     Abstract available
    
    
    February 2026
38. CHEN L, Li J, Li K, Hu J, et al
    Corrigendum to "Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy". [Radiother Oncol. 190 (2024) 109985].
    Radiother Oncol. 2026;217:111439.
    PubMed    
    
    
    
39. TAWK B, Halec G, Rein K, Schwager C, et al
    A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C).
    Radiother Oncol. 2026;217:111433.
    PubMed     Abstract available
    
    
    January 2026
40. ZHANG H, Ding J, Zhang L, Li J, et al
    MRI-based multilevel radiomics and transformer features for predicting radiation-induced carotid artery injury after nasopharyngeal carcinoma radiotherapy: A multicenter study.
    Radiother Oncol. 2026 Jan 24:111390. doi: 10.1016/j.radonc.2026.111390.
    PubMed     Abstract available
    
    
    
41. EHRET F, Grimm J, Subedi G, Vorbach SM, et al
    Tumor control probability modeling of pulmonary metastases in oligometastatic head and neck squamous cell carcinoma treated with stereotactic body radiation therapy.
    Radiother Oncol. 2026 Jan 8:111375. doi: 10.1016/j.radonc.2026.111375.
    PubMed     Abstract available
    
    
    
42. MANDUCHI B, Jefferson TC, Moreno AC, Barbon CEA, et al
    Individual patient-reported symptom items discriminate imaging-graded dysphagia in head and neck cancer patients treated with radiotherapy: secondary analysis of pooled prospective studies.
    Radiother Oncol. 2026 Jan 6:111365. doi: 10.1016/j.radonc.2026.111365.
    PubMed     Abstract available
    
    
    
43. XU Q, Shen H, Wen L, Tu C, et al
    Development and validation of A CCTA-based risk prediction model for major adverse cardiovascular events in esophageal cancer patients receiving radiotherapy.
    Radiother Oncol. 2026 Jan 6:111364. doi: 10.1016/j.radonc.2026.111364.
    PubMed     Abstract available
    
    
    
44. CHEN B, Wang D, Huang J, Yu S, et al
    A seven-gene 5-hydroxymethylcytosine signature in circulating cell-free DNA for prognostic stratification of nasopharyngeal carcinoma.
    Radiother Oncol. 2026 Jan 5:111366. doi: 10.1016/j.radonc.2026.111366.
    PubMed     Abstract available
    
    
    
45. LOOMAN EL, van Zon-Meijer TWH, Ruhle A, Schafer H, et al
    Patterns of lymphatic spread in hypopharyngeal squamous cell carcinoma - Findings from a multicenter study.
    Radiother Oncol. 2026;214:111319.
    PubMed     Abstract available
    
    
    
46. TYYGER M, Iyizoba-Ebozue Z, Nicklin E, Boele F, et al
    Associations between patient-reported neurocognition, mood, and fatigue and radiation dose in oropharyngeal cancer survivors.
    Radiother Oncol. 2026;214:111309.
    PubMed     Abstract available
    
    
    
47. YOU J, Ou H, Zhang Y, Wu X, et al
    NPC-SurvAI: A fully automated deep learning framework for prognostic prediction and risk stratification in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2026;214:111223.
    PubMed     Abstract available
    
    
    December 2025
48. UGWU GC, Jalali F, Liu G, Li G, et al
    The actual performance of ML/AI models in predicting radiation-induced toxicity in head and neck cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2025;216:111350.
    PubMed     Abstract available
    
    
    
49. MAURY P, Sayous Y, Vernerey D, Sun XS, et al
    Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process.
    Radiother Oncol. 2025;214:111316.
    PubMed     Abstract available
    
    
    November 2025
50. NACHANKAR A, Gora J, Schafasand M, Fuss M, et al
    Impact of dose and dose-averaged linear energy transfer on oro-pharyngeal-mucosal toxicity in patients with non-squamous head and neck cancers treated with carbon-ion radiotherapy.
    Radiother Oncol. 2025;214:111314.
    PubMed     Abstract available
    
    
    
51. BANG C, Gautier H, Le WT, Lalonde A, et al
    Dynamic prediction of Radiotherapy toxicities in Head and neck cancer using clinical and imaging data.
    Radiother Oncol. 2025 Nov 26:111312. doi: 10.1016/j.radonc.2025.111312.
    PubMed     Abstract available
    
    
    
52. LIU Y, Populaire P, Draguet C, Haustermans K, et al
    Integrating photon with proton dose-response data alters a pulmonary complication model-based patient selection in esophageal cancer.
    Radiother Oncol. 2025 Nov 19:111289. doi: 10.1016/j.radonc.2025.111289.
    PubMed     Abstract available
    
    
    
53. NIKITAS J, Ma TM, Cook K, Woods K, et al
    Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy.
    Radiother Oncol. 2025;214:111283.
    PubMed     Abstract available
    
    
    
54. AL-MAMGANI A, Verduijn GM, Zwijnenburg E, Schreuder WH, et al
    Brachytherapy (Interventional Radiotherapy) for lip carcinoma: excellent local control, low toxicity profile, and high patient satisfaction - The Dutch experience from four brachytherapy-dedicated head and neck cancer centers.
    Radiother Oncol. 2025;214:111243.
    PubMed     Abstract available
    
    
    October 2025
55. SATO M, Hirose K
    Corrigendum to "Efficacy and safety of boron neutron capture therapy for Hypopharyngeal/Laryngeal cancer patients with previous head and neck irradiation". [Radiother. Oncol. 198 (2024) 110382].
    Radiother Oncol. 2025;214:111228.
    PubMed    
    
    
    
56. LINDEN SML, Philippens MEP, Sher DJ, Sanders ME, et al
    Risk of dysfunctional larynx after radiotherapy for early-stage glottic laryngeal cancer: A systematic review and meta-analysis.
    Radiother Oncol. 2025;214:111226.
    PubMed     Abstract available
    
    
    
57. GREGOIRE V, Tao Y, Kaanders J, Machiels JP, et al
    An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC).
    Radiother Oncol. 2025;214:111227.
    PubMed     Abstract available
    
    
    
58. VAN DEN BOSCH S, Cox MC, Doornaert PAH, Hoebers FJP, et al
    Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial.
    Radiother Oncol. 2025 Oct 5:111196. doi: 10.1016/j.radonc.2025.111196.
    PubMed     Abstract available
    
    
    
59. JIN X, Zeng X, Yang D, Yi L, et al
    High-dose ionizing radiation-induced ferroptosis leads to radiotherapy sensitization of nasopharyngeal carcinoma.
    Radiother Oncol. 2025 Oct 5:111166. doi: 10.1016/j.radonc.2025.111166.
    PubMed     Abstract available
    
    
    September 2025
60. DE VETTE SPM, Neh H, van der Hoek L, MacRae DC, et al
    Deep learning NTCP model for late dysphagia after radiotherapy for head and neck cancer patients based on 3D dose, CT and segmentations.
    Radiother Oncol. 2025;213:111169.
    PubMed     Abstract available
    
    
    
61. CHENG N, Chen Z, Chen Y, Hu Y, et al
    18F-FDG PET/CT directed radiotherapy dose escalation in locally advanced esophageal cancer (LAEC), a phase I study.
    Radiother Oncol. 2025;213:111176.
    PubMed     Abstract available
    
    
    
62. NIELSEN SB, Kristensen MH, Holm AIS, Zukauskaite R, et al
    Failure pattern and salvage in head and neck cancer of unknown primary: A national study by DAHANCA.
    Radiother Oncol. 2025;213:111162.
    PubMed     Abstract available
    
    
    
63. ZHANG M, Gong J, Zhu Y, Yang ZH, et al
    A predictive model based on the dosimetric parameters of the parotid stem cell region to assess the recovery of radiation-induced xerostomia in long-term survivors of nasopharyngeal carcinoma after radical radiotherapy.
    Radiother Oncol. 2025;213:111163.
    PubMed     Abstract available
    
    
    
64. MUIJS CT, Klaver YLB, Nuyttens J, Lips IM, et al
    National indication protocol for proton radiotherapy in esophageal cancer patients in the Netherlands.
    Radiother Oncol. 2025 Sep 24:111164. doi: 10.1016/j.radonc.2025.111164.
    PubMed     Abstract available
    
    
    
65. HE SQ, Lv SH, Wen SQ, Lin-Wang, et al
    Efficacy of metastatic lesion radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving local regional radiotherapy and chemo-immunotherapy: a multicenter retrospective study.
    Radiother Oncol. 2025;213:111160.
    PubMed     Abstract available
    
    
    
66. LIU Y, Su Y, Peng J, Zhang W, et al
    A multidimensional deep ensemble learning model predicts pathological response and outcomes in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy from pretreatment CT imaging: A multicenter study.
    Radiother Oncol. 2025 Sep 10:111133. doi: 10.1016/j.radonc.2025.111133.
    PubMed     Abstract available
    
    
    
67. GAU M, Alfaraj FA, Huang SH, O'Sullivan B, et al
    Unilateral vs bilateral neck irradiation: The importance of careful patient selection in tailoring radiation therapy for lateralized palatine-tonsil and non-palatine-tonsil oropharyngeal carcinoma.
    Radiother Oncol. 2025;210:111049.
    PubMed     Abstract available
    
    
    August 2025
68. WONG HCY, Karam I, Corbin K, Tse SSW, et al
    Bao Yuan Gao vs. Calendula cream for radiotherapy-induced skin toxicity in head and neck cancer: A randomized controlled trial - A biased negative trial essentially.
    Radiother Oncol. 2025;211:111109.
    PubMed    
    
    
    
69. HANSEN CR, Samsoe E, Smulders B, Sand HMB, et al
    Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial.
    Radiother Oncol. 2025;211:111096.
    PubMed     Abstract available
    
    
    
70. TUO A, Moon DH, Avkshtol V, Shah JL, et al
    Associations between dosimetry and patient-reported outcomes in oropharyngeal cancer: post hoc analysis of elective neck de-escalation trials.
    Radiother Oncol. 2025;209:110933.
    PubMed     Abstract available
    
    
    July 2025
71. YANG C, Shen M, Long L, Meng Z, et al
    The potential value of IVIM MR for radiation-related hypothyroidism in nasopharyngeal carcinoma.
    Radiother Oncol. 2025;211:111065.
    PubMed     Abstract available
    
    
    
72. CHEN ZH, Han X, Lin L, Lin GY, et al
    Harnessing deep learning to optimize induction chemotherapy choices in nasopharyngeal carcinoma.
    Radiother Oncol. 2025;211:111047.
    PubMed     Abstract available
    
    
    
73. ZHENG S, Liu Y, He Z, He S, et al
    CNG (Collaborative Nasopharyngeal Carcinoma Group) stage: Improved prognostic stratification of nasopharyngeal carcinoma and association with Epstein-Barr virus DNA in the intensity-modulated radiation therapy era.
    Radiother Oncol. 2025;210:111051.
    PubMed     Abstract available
    
    
    
74. PETRELLI F, Trevisan F, Nardone M, Carioli D, et al
    Non-cisplatin concurrent agents plus definitive radiotherapy for locally advanced head and neck cancer: A network meta-analysis of randomized studies.
    Radiother Oncol. 2025 Jul 14:111033. doi: 10.1016/j.radonc.2025.111033.
    PubMed     Abstract available
    
    
    
75. DE LEEUW ALMP, Hoebers FJP, Giralt J, Tao Y, et al
    Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trial.
    Radiother Oncol. 2025;210:111044.
    PubMed     Abstract available
    
    
    
76. JENSEN K, Holm AIS, Eriksen JG, Skyt PS, et al
    Danish Head and Neck Cancer Group (DAHANCA) Radiotherapy Quality Assurance Guidelines 2025. Update and new chapters: Planning of complex targets, hypofractionation, planning of reirradiation, target definition after induction chemotherapy, and clarifi
    Radiother Oncol. 2025;210:111028.
    PubMed    
    
    
    
77. PERREARD M, Florent R, Divoux J, Bastit V, et al
    Use of patient-derived tumor organoids from head and neck squamous cell carcinoma for the evaluation of the differential effect of carbon ions over X-rays.
    Radiother Oncol. 2025 Jul 3:111026. doi: 10.1016/j.radonc.2025.111026.
    PubMed     Abstract available
    
    
    
78. LIU ZQ, Zang SB, OuYang PY, Jing BZ, et al
    Multimodal prognostic model for de novo metastatic nasopharyngeal carcinoma after first-line immunochemotherapy.
    Radiother Oncol. 2025 Jul 1:111010. doi: 10.1016/j.radonc.2025.111010.
    PubMed     Abstract available
    
    
    
79. YANG F, Wang D, Su Y, Tang J, et al
    The dynamic changes of glymphatic function at different post-radiotherapy stages in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2025 Jul 1:111012. doi: 10.1016/j.radonc.2025.111012.
    PubMed     Abstract available
    
    
    June 2025
80. POPULAIRE P, Defraene G, Liu Y, Titt U, et al
    Dose to the left ventricle is associated to the risk of acute cardiac toxicity in patients with esophageal cancer undergoing trimodality treatment.
    Radiother Oncol. 2025;209:111002.
    PubMed     Abstract available
    
    
    
81. ZHENG Q, Yu X, Pan W, Ai Y, et al
    Deep learning dosiomics in grade 4 radiation-induced lymphopenia prediction in radiotherapy for esophageal cancer: a multi-center study.
    Radiother Oncol. 2025;209:110995.
    PubMed     Abstract available
    
    
    
82. LI Y, Liang J, Fu G, Pan J, et al
    Non-linear early rapid hippocampal atrophy and associated microstructural injury in patients with nasopharyngeal carcinoma after radiotherapy: Implications for hippocampal protection.
    Radiother Oncol. 2025;209:110997.
    PubMed     Abstract available
    
    
    
83. LI J, He HG, Guan C, Ding Y, et al
    Dynamic joint prediction model of severe radiation-induced oral mucositis among nasopharyngeal carcinoma: a prospective longitudinal study.
    Radiother Oncol. 2025;209:110993.
    PubMed     Abstract available
    
    
    
84. MOHARRAMI M, Watson E, Huang SH, Madathil S, et al
    Defining the optimal radiation thresholds for Stratifying jaw osteoradionecrosis risk in head and neck cancer.
    Radiother Oncol. 2025;209:110996.
    PubMed     Abstract available
    
    
    
85. BACHMANN N, Ahmadsei M, Hurlimann M, Gabrys HS, et al
    Cone-beam computed tomography-based online adaptive radiotherapy of esophageal cancer in the neoadjuvant setting: Dosimetric analysis, toxicity and treatment response.
    Radiother Oncol. 2025;209:110981.
    PubMed     Abstract available
    
    
    
86. NGAN TH, Yeh SH, Tien HJ, Hsu CX, et al
    Bao Yuan Gao vs. Calendula cream for radiotherapy-induced skin toxicity in head and neck cancer: A randomized controlled trial.
    Radiother Oncol. 2025;209:110976.
    PubMed     Abstract available
    
    
    
87. NIELSEN AM, Laursen MRT, Rechner LA, Krog SM, et al
    Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial.
    Radiother Oncol. 2025;207:110906.
    PubMed     Abstract available
    
    
    
88. YARLAGADDA S, Rohe RM, McNeill V, Nemec JR, et al
    Tubarial gland sparing for oropharyngeal cancer: Feasibility with intensity modulated proton therapy & intensity modulated radiation therapy.
    Radiother Oncol. 2025;207:110882.
    PubMed     Abstract available
    
    
    
89. GAWRYSZUK A, van der Laan HP, Vergeer MR, Veening M, et al
    Improved NTCP model for late radiation-induced aspiration based on dose delivered to specific aspiration-related OARs.
    Radiother Oncol. 2025;207:110871.
    PubMed     Abstract available
    
    
    
90. HUGHES A, Johnny C, Huang SH, Su J, et al
    The prognostic and predictive value of pre-treatment hematologic markers for oropharyngeal carcinoma stratified by HPV status and treated with definitive (chemo) radiation.
    Radiother Oncol. 2025;207:110851.
    PubMed     Abstract available
    
    
    
91. MA B, Guo J, Dijk LVV, Langendijk JA, et al
    PET and CT based DenseNet outperforms advanced deep learning models for outcome prediction of oropharyngeal cancer.
    Radiother Oncol. 2025;207:110852.
    PubMed     Abstract available
    
    
    May 2025
92. XIANG Z, Yu X, Lin S, Wang D, et al
    Deep learning dosiomics for the pretreatment prediction of radiation dermatitis in nasopharyngeal carcinoma patients treated with radiotherapy.
    Radiother Oncol. 2025 May 22:110951. doi: 10.1016/j.radonc.2025.110951.
    PubMed     Abstract available
    
    
    
93. YI X, Yu X, Li C, Li J, et al
    Deep learning Radiopathomics based on pretreatment MRI and whole slide images for predicting overall survival in locally advanced nasopharyngeal carcinoma.
    Radiother Oncol. 2025;209:110949.
    PubMed     Abstract available
    
    
    
94. DING J, Yin X, Lin Y, Liao X, et al
    Transforming the management of radiotherapy-induced hypothyroidism in nasopharyngeal carcinoma through an Innovative individualized radiation dosage model: A multicenter retrospective analysis.
    Radiother Oncol. 2025;208:110943.
    PubMed     Abstract available
    
    
    
95. CHEN SY, Duan XT, Xie RL, Han YQ, et al
    Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2025 May 2:110913. doi: 10.1016/j.radonc.2025.110913.
    PubMed     Abstract available
    
    
    
96. KONG W, Huiskes M, Habraken SJM, Astreinidou E, et al
    'iCycle-pBAO': Automated patient-specific beam-angle selection in proton therapy applied to oropharyngeal cancer.
    Radiother Oncol. 2025;206:110799.
    PubMed     Abstract available
    
    
    
97. CARSUZAA F, Favier V, Seguin L, Turri-Zanoni M, et al
    Consensus for a postoperative atlas of sinonasal substructures from a modified Delphi study to guide radiotherapy in sinonasal malignancies.
    Radiother Oncol. 2025;206:110784.
    PubMed     Abstract available
    
    
    April 2025
98. YAN Y, Zhao F
    Response to the commentary on "Optimizing fractionation schedules for de-escalation radiotherapy in head and neck cancers using deep reinforcement learning" by Mohammad Zahid, and Heiko Enderling.
    Radiother Oncol. 2025;208:110903.
    PubMed    
    
    
    
99. ERIKSEN JG, Maare C, Johansen J, Primdahl H, et al
    DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.
    Radiother Oncol. 2025 Apr 19:110899. doi: 10.1016/j.radonc.2025.110899.
    PubMed     Abstract available
    
    
    
100. CAVALIERI S, Brakenhoff RH, Leemans CR, Hoebers FJP, et al
     Prognostic gene expression signatures for HPV-negative head and neck squamous cell carcinoma.
     Radiother Oncol. 2025 Apr 17:110900. doi: 10.1016/j.radonc.2025.110900.
     PubMed     Abstract available
     
     
     
101. WANG Z, Li L, Wu Y, Liu Z, et al
     Development and validation of Prediction models for radiation-induced hypoglossal neuropathy in patients with nasopharyngeal carcinoma.
     Radiother Oncol. 2025 Apr 8:110887. doi: 10.1016/j.radonc.2025.110887.
     PubMed     Abstract available
     
     
     
102. HIRAOKA S, Hirashima H, Nakamura M, Tanaka F, et al
     Integration test of biaxially rotational dynamic-radiation therapy for nasopharyngeal carcinoma: Efficacy evaluation and dosimetric analysis.
     Radiother Oncol. 2025;207:110879.
     PubMed     Abstract available
     
     
     
103. YANG F, Peng W, Wei H, Li X, et al
     Pretreatment arterial spin labeling combined with radiological depth of invasion predicts treatment outcome in nonmetastatic NPC.
     Radiother Oncol. 2025;205:110765.
     PubMed     Abstract available
     
     
     March 2025
104. ZENG Y, Hu Y, Wang L, Liao Z, et al
     Control of dental calculus Prevents severe Radiation-Induced oral mucositis in patients undergoing radiotherapy for nasopharyngeal carcinoma.
     Radiother Oncol. 2025 Mar 27:110872. doi: 10.1016/j.radonc.2025.110872.
     PubMed     Abstract available
     
     
     
105. LI R, Wang X, Luo J, Bai H, et al
     Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trials.
     Radiother Oncol. 2025;207:110867.
     PubMed     Abstract available
     
     
     
106. YAN Y, Sun X, Chen Y, Sun Z, et al
     Optimizing fractionation schedules for de-escalation radiotherapy in head and neck cancers using deep reinforcement learning.
     Radiother Oncol. 2025;207:110833.
     PubMed     Abstract available
     
     
     
107. KRISTENSEN MH, Nielsen SB, Alsner J, Sander Holm AI, et al
     A systematic review and proportional meta-analysis of image-based pattern of loco-regional failure analyses outcomes in head and neck squamous cell carcinoma.
     Radiother Oncol. 2025 Mar 13:110838. doi: 10.1016/j.radonc.2025.110838.
     PubMed     Abstract available
     
     
     
108. ZAYED S, Lang P, Read N, Correa RJM, et al
     Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial.
     Radiother Oncol. 2025 Mar 5:110831. doi: 10.1016/j.radonc.2025.110831.
     PubMed     Abstract available
     
     
     February 2025
109. ANTUNES J, Young T, Pittock D, Jacobs P, et al
     Assessing multiple MRI sequences in deep learning-based synthetic CT generation for MR-only radiation therapy of head and neck cancers.
     Radiother Oncol. 2025 Feb 8:110782. doi: 10.1016/j.radonc.2025.110782.
     PubMed     Abstract available
     
     
     
110. VAN DER LAAN HP, Gawryszuk A, van der Schaaf A, Langendijk JA, et al
     Risk reduction of radiation-induced aspiration by sparing specific aspiration-related-organs at risk; an in silico feasibility study.
     Radiother Oncol. 2025;203:110698.
     PubMed     Abstract available
     
     
     January 2025
111. WAN D, Liu Q, Wei JS
     Comment on "Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study".
     Radiother Oncol. 2025;205:110767.
     PubMed    
     
     
     
112. ZHAO C, Miao J
     Response to Dr. Dan Wan, Qing Liu, and Jia-Sha Wei's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Comment on "Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiat
     Radiother Oncol. 2025 Jan 30:110768. doi: 10.1016/j.radonc.2025.110768.
     PubMed    
     
     
     
113. ZHONG J, Chen H, Chen X, Ma N, et al
     Identifying adverse nodal features associated with poor prognosis in stage IB nasopharyngeal carcinoma patients based on the 9th AJCC/UICC staging system: Implications for treatment intensification.
     Radiother Oncol. 2025;205:110747.
     PubMed     Abstract available
     
     
     
114. NEH H, de Vette SPM, Stoffers RH, Zhou G, et al
     Normal tissue complication probability model predicting taste impairment in head and neck cancer patients: Evaluating the taste bud bearing tongue mucosa as a predictor.
     Radiother Oncol. 2025 Jan 28:110746. doi: 10.1016/j.radonc.2025.110746.
     PubMed     Abstract available
     
     
     
115. TORAIH E, Hussein M, Elshazli R, Abdelmaksoud A, et al
     Therapeutic outcomes and safety of radiofrequency ablation for primary papillary thyroid carcinoma: A game-changing meta-analysis.
     Radiother Oncol. 2025;205:110706.
     PubMed     Abstract available
     
     
     
116. RAJENDRAN P, Yang Y, Niedermayr TR, Gensheimer M, et al
     Large language model-augmented learning for auto-delineation of treatment targets in head-and-neck cancer radiotherapy.
     Radiother Oncol. 2025;205:110740.
     PubMed     Abstract available
     
     
     
117. NERICH V, Falcoz A, Nadin L, Meurisse A, et al
     Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer.
     Radiother Oncol. 2025;204:110726.
     PubMed     Abstract available
     
     
     
118. CHEN L, Li J, Li K, Hu J, et al
     Corrigendum to "Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy" [Radiother. Oncol. 190 (2024) 109985].
     Radiother Oncol. 2025;204:110719.
     PubMed    
     
     
     
119. LU T, Gao X, Yu Z, Liu L, et al
     Reducing radiation-induced hypothyroidism by modified delineation of cervical lymphatic drainage area for nasopharyngeal carcinoma treated by intensity-modulated radiation Therapy: 3 years' experience.
     Radiother Oncol. 2025;204:110713.
     PubMed     Abstract available
     
     
     
120. KAMPEL L, Feldstein S, Tsuriel S, Trejo LL, et al
     TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma.
     Radiother Oncol. 2025;204:110714.
     PubMed     Abstract available
     
     
     
121. MENG X, Ju Z, Sakai M, Li Y, et al
     Normal tissue complication probability model for acute oral mucositis in patients with head and neck cancer undergoing carbon ion radiation therapy based on dosimetry, radiomics, and dosiomics.
     Radiother Oncol. 2025;204:110709.
     PubMed     Abstract available
     
     
     
122. ZHANG L, Zhang Z, Wang Y, Zhu Y, et al
     Evaluation of machine learning models for predicting xerostomia in adults with head and neck cancer during proton and heavy ion radiotherapy.
     Radiother Oncol. 2025;204:110712.
     PubMed     Abstract available
     
     
     
123. LIU Y, Chen Z, Zhou Q, Shang X, et al
     A feasibility study of dose-band prediction in radiation therapy: Predicting a spectrum of plan dose.
     Radiother Oncol. 2025;202:110593.
     PubMed     Abstract available
     
     
     December 2024
124. WINTER RM, Boeke S, Leibfarth S, Habrich J, et al
     Clinical validation of a prognostic preclinical magnetic resonance imaging biomarker for radiotherapy outcome in head-and-neck cancer.
     Radiother Oncol. 2024;204:110702.
     PubMed     Abstract available
     
     
     
125. RUHLE A, Weymann M, Behrens M, Olbrich J, et al
     Predicting cisplatin tolerability in older adults with head and neck cancer - Insights for improved chemoradiation outcomes.
     Radiother Oncol. 2024 Dec 24:110697. doi: 10.1016/j.radonc.2024.110697.
     PubMed     Abstract available
     
     
     
126. GIRAUD P, Guihard S, Thureau S, Guilbert P, et al
     Prediction of the need of enteral nutrition during radiation therapy for head and neck cancers.
     Radiother Oncol. 2024 Dec 21:110693. doi: 10.1016/j.radonc.2024.110693.
     PubMed     Abstract available
     
     
     
127. HE SQ, Liu GY, Yu YH, Wang L, et al
     Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.
     Radiother Oncol. 2024 Dec 19:110687. doi: 10.1016/j.radonc.2024.110687.
     PubMed     Abstract available
     
     
     
128. ZHANG S, Yan L, Li R, Zhao Y, et al
     Development and validation of a nomogram to predict overall survival in patients with External auditory canal cancer.
     Radiother Oncol. 2024 Dec 19:110691. doi: 10.1016/j.radonc.2024.110691.
     PubMed     Abstract available
     
     
     
129. HUANG X, Lin K, Chen W, Zhang D, et al
     Modulation of the local angiotensin II: Augmentation of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1alpha-HILPDA axis.
     Radiother Oncol. 2024 Dec 19:110686. doi: 10.1016/j.radonc.2024.110686.
     PubMed     Abstract available
     
     
     
130. KOCH A, Reinhardt P, Elicin O, Aebersold DM, et al
     Predictive biomarkers of radiotherapy- related dermatitis, xerostomia, mucositis and dysphagia in head and neck cancer: A systematic review.
     Radiother Oncol. 2024 Dec 18:110689. doi: 10.1016/j.radonc.2024.110689.
     PubMed     Abstract available
     
     
     
131. LIANG JL, Wen YF, Huang YP, Guo J, et al
     A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study.
     Radiother Oncol. 2024;203:110660.
     PubMed     Abstract available
     
     
     
132. LI R, Zhao Y, Wu K, Li H, et al
     p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy?
     Radiother Oncol. 2024;201:110578.
     PubMed     Abstract available
     
     
     November 2024
133. MALLICK S
     Response to "Optimizing palliative radiation: Beyond dose escalation in advanced head and neck squamous cell carcinoma".
     Radiother Oncol. 2024;202:110656.
     PubMed    
     
     
     
134. SHI X, Hui B, Wang Y, Lu Y, et al
     Optimizing palliative radiation: Beyond dose escalation in advanced head and neck squamous cell carcinoma.
     Radiother Oncol. 2024 Nov 29:110655. doi: 10.1016/j.radonc.2024.110655.
     PubMed    
     
     
     
135. JIMENEZ-LABAIG P, Aymerich C, Rullan A, Cacicedo J, et al
     Prevalence of depressive and anxiety symptoms in patients with head and neck cancer undergoing radiotherapy: A systematic review and meta-analysis of longitudinal studies.
     Radiother Oncol. 2024;202:110649.
     PubMed     Abstract available
     
     
     
136. WU CN, Wang JD, Chen WC, Lin CY, et al
     Intensity-modulated proton therapy versus volumetric-modulated ARC therapy in patients with nasopharyngeal carcinoma: A long-term, multicenter cohort study.
     Radiother Oncol. 2024 Nov 23:110648. doi: 10.1016/j.radonc.2024.110648.
     PubMed     Abstract available
     
     
     
137. LIU M, Pang B, Chen S, Zeng Y, et al
     Deep learning-based multiple-CT optimization: An adaptive treatment planning approach to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers.
     Radiother Oncol. 2024;202:110650.
     PubMed     Abstract available
     
     
     
138. URSINO S, Malfatti G, Felice F, Bonomo P, et al
     Deglutition preservation after swallowing (Swoars)-sparing IMRT in head and neck cancers: Definitive results of A multicenter prospective study of the italian association of radiotherapy and clinical oncology (Airo).
     Radiother Oncol. 2024 Nov 22:110651. doi: 10.1016/j.radonc.2024.110651.
     PubMed     Abstract available
     
     
     
139. HUANG LW, Pan JW, Li B, Wu WX, et al
     Evaluation of radiation induced brain injury in nasopharyngeal carcinoma patients based on multi-parameter quantitative MRI: A prospective longitudinal study.
     Radiother Oncol. 2024 Nov 11:110621. doi: 10.1016/j.radonc.2024.110621.
     PubMed     Abstract available
     
     
     
140. ZHU MY, Wu HJ, Fang T, Zhang GS, et al
     Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study.
     Radiother Oncol. 2024 Nov 11:110620. doi: 10.1016/j.radonc.2024.110620.
     PubMed     Abstract available
     
     
     
141. MALLICK S, Dagar A, Ghosh A, Aashita, et al
     Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.
     Radiother Oncol. 2024 Nov 8:110611. doi: 10.1016/j.radonc.2024.110611.
     PubMed     Abstract available
     
     
     
142. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
     Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer.
     Radiother Oncol. 2024 Nov 8:110612. doi: 10.1016/j.radonc.2024.110612.
     PubMed     Abstract available
     
     
     
143. VAN BRUGGEN IG, van Dijk M, Brinkman-Akker MJ, Lofman F, et al
     Clinical implementation of deep learning robust IMPT planning in oropharyngeal cancer patients: A blinded clinical study.
     Radiother Oncol. 2024;200:110522.
     PubMed     Abstract available
     
     
     
144. YANG WC, Koto M, Ikawa H, Imai R, et al
     Clinical target volume design and dose in carbon-ion radiation therapy for sinonasal mucosal melanoma.
     Radiother Oncol. 2024;200:110511.
     PubMed     Abstract available
     
     
     
145. XU MH, Dou JP, Guo MH, Yi WQ, et al
     Risk factors for recurrent laryngeal nerve injury in microwave ablation of thyroid nodules: A multicenter study.
     Radiother Oncol. 2024;200:110516.
     PubMed     Abstract available
     
     
     
146. CHEN AM
     De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: Who, why, what, where, when, how, how much...and what next?
     Radiother Oncol. 2024;200:110373.
     PubMed     Abstract available
     
     
     
147. CHEN B, Zhan Z, Xu Y, Yu S, et al
     Long-term trends in the burden of nasopharyngeal carcinoma in China: A comprehensive analysis from 1990 to 2021 and projections to 2030 based on the global burden of disease study 2021.
     Radiother Oncol. 2024 Nov 1:110613. doi: 10.1016/j.radonc.2024.110613.
     PubMed     Abstract available
     
     
     October 2024
148. TATTENBERG S, Shin J, Hoehr C, Sung W, et al
     Correlation of dynamic blood dose with clinical outcomes in radiotherapy for head-and-neck cancer.
     Radiother Oncol. 2024 Oct 29:110603. doi: 10.1016/j.radonc.2024.110603.
     PubMed     Abstract available
     
     
     
149. GAITO S, Hwang E, Thwaites D, Ahern V, et al
     Identifying paediatric patients at risk of severe hearing impairment after treatment for malignancies of the H&N/CNS with proton therapy.
     Radiother Oncol. 2024 Oct 26:110597. doi: 10.1016/j.radonc.2024.110597.
     PubMed     Abstract available
     
     
     
150. FELDMAN J, Pryanichnikov A, Shwartz D, Hillman Y, et al
     Study of upright patient positioning reproducibility in image-guided proton therapy for head and neck cancers.
     Radiother Oncol. 2024;201:110572.
     PubMed     Abstract available
     
     
     
151. LIANG Z, Luo C, Li S, Zhu Y, et al
     Guiding induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma with ternary classification of predicted individual treatment effect.
     Radiother Oncol. 2024 Oct 9:110571. doi: 10.1016/j.radonc.2024.110571.
     PubMed     Abstract available
     
     
     
152. PAN J, Qiu Z, Fu G, Liang J, et al
     Non-complete recovery of temporal lobe white matter diffusion metrics at one year Post-Radiotherapy: Implications for Radiation-Induced necrosis risk.
     Radiother Oncol. 2024;199:110420.
     PubMed     Abstract available
     
     
     September 2024
153. THIRUVENGADAM R, Kim SH, Thiruvengadam M
     Fructose 1,6-bisphosphate aldolase: A promising prognostic marker for oral cancer and its role in radiotherapy response.
     Radiother Oncol. 2024;200:110537.
     PubMed     Abstract available
     
     
     
154. DAVE J
     Concerns regarding the use of only phase 2 study to Justify palliative radiotherapy vs. Palliative chemo-radiotherapy in unresectable head and neck cancer.
     Radiother Oncol. 2024;200:110526.
     PubMed    
     
     
     
155. KONG W, Huiskes M, Habraken SJM, Astreinidou E, et al
     Reducing the lateral dose penumbra in IMPT by incorporating transmission pencil beams.
     Radiother Oncol. 2024;198:110388.
     PubMed     Abstract available
     
     
     August 2024
156. YANG Y, Shao R, Cao X, Chen M, et al
     Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials.
     Radiother Oncol. 2024;200:110517.
     PubMed     Abstract available
     
     
     
157. ZHU WY, Huang J, Lu ZQ, Yang S, et al
     Management of post-radiation carotid blowout syndrome in patients with head and neck cancer: A systematic review.
     Radiother Oncol. 2024;200:110502.
     PubMed     Abstract available
     
     
     
158. CHEN L, Wang H, Chen W, Li K, et al
     Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma.
     Radiother Oncol. 2024 Aug 25:110497. doi: 10.1016/j.radonc.2024.110497.
     PubMed     Abstract available
     
     
     
159. REINEMA FV, Hudson N, Adema GJ, Peeters WJM, et al
     MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells.
     Radiother Oncol. 2024;200:110503.
     PubMed     Abstract available
     
     
     
160. BEUKEMA JC, Haveman JW, Langendijk JA, Oldehinkel E, et al
     Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: A prospective cohort study.
     Radiother Oncol. 2024;200:110479.
     PubMed     Abstract available
     
     
     
161. TOPKAN E, Somay E, Selek U
     Comment on: Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
     Radiother Oncol. 2024;199:110467.
     PubMed    
     
     
     
162. MA B, Guo J, De Biase A, van Dijk LV, et al
     PET/CT based transformer model for multi-outcome prediction in oropharyngeal cancer.
     Radiother Oncol. 2024;197:110368.
     PubMed     Abstract available
     
     
     July 2024
163. SATO M, Hirose K
     A simple prediction model for the risk of boron neutron capture therapy-induced nausea and vomiting in head and neck cancer.
     Radiother Oncol. 2024;199:110464.
     PubMed     Abstract available
     
     
     
164. MENESES AG, Ferreira EB, Vieira LAC, Bontempo PSM, et al
     Comparison of liposomal gel with and without addition of chamomile for prevention of radiation dermatitis in head and neck cancer patients: A randomized controlled trial.
     Radiother Oncol. 2024;199:110440.
     PubMed     Abstract available
     
     
     
165. XIE C, Yu X, Tan N, Zhang J, et al
     Combined deep learning and radiomics in pretreatment radiation esophagitis prediction for patients with esophageal cancer underwent volumetric modulated arc therapy.
     Radiother Oncol. 2024;199:110438.
     PubMed     Abstract available
     
     
     
166. ZUKAUSKAITE R, Kristensen MH, Eriksen JG, Johansen J, et al
     Comparison of 3-year local control using DAHANCA radiotherapy guidelines before and after implementation of five millimetres geometrical GTV to high-dose CTV margin.
     Radiother Oncol. 2024;196:110284.
     PubMed     Abstract available
     
     
     
167. CHIANG CL, Chan KSK, Li H, Ng WT, et al
     Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.
     Radiother Oncol. 2024;196:110287.
     PubMed     Abstract available
     
     
     
168. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
     Response to letter to the editor by Somay et al., re: "Risk factors associated with the development of osteoradionecrosis (ORN) in head and neck cancer patients in Ireland: A 10-year retrospective review".
     Radiother Oncol. 2024 Jul 1:110412. doi: 10.1016/j.radonc.2024.110412.
     PubMed    
     
     
     June 2024
169. NAVRAN A, Kayembe MT, Gouw ZAR, Vogel WV, et al
     FGD-PET/CT three months after (chemo)radiotherapy for head and neck squamous cell carcinoma spares considerable number of patients from a salvage neck dissection.
     Radiother Oncol. 2024;198:110407.
     PubMed     Abstract available
     
     
     
170. TOPKAN E, Somay E, Selek U
     Letter to the editor regarding "Risk factors associated with the development of osteoradionecrosis (ORN) in head and neck cancer patients in Ireland: A 10-year retrospective review".
     Radiother Oncol. 2024 Jun 25:110411. doi: 10.1016/j.radonc.2024.110411.
     PubMed    
     
     
     
171. CANTERS R, van der Klugt K, Trier Taasti V, Buijsen J, et al
     Robustness of intensity modulated proton treatment of esophageal cancer for anatomical changes and breathing motion.
     Radiother Oncol. 2024 Jun 23:110409. doi: 10.1016/j.radonc.2024.110409.
     PubMed     Abstract available
     
     
     
172. SATO M, Hirose K
     Efficacy and safety of boron neutron capture therapy for Hypopharyngeal/Laryngeal cancer patients with previous head and neck irradiation in Japan.
     Radiother Oncol. 2024 Jun 14:110382. doi: 10.1016/j.radonc.2024.110382.
     PubMed     Abstract available
     
     
     
173. MOORE-PALHARES D, Saifuddin M, Dasgupta A, Anzola Pena ML, et al
     Radiation enhancement using focussed ultrasound-stimulated microbubbles for head and neck cancer: A phase 1 clinical trial.
     Radiother Oncol. 2024;198:110380.
     PubMed     Abstract available
     
     
     
174. ZHOU H, Zhao Q, Huang W, Liang Z, et al
     A novel fully automatic segmentation and counting system for metastatic lymph nodes on multimodal magnetic resonance Imaging: Evaluation and prognostic implications in Nasopharyngeal carcinoma.
     Radiother Oncol. 2024 Jun 2:110367. doi: 10.1016/j.radonc.2024.110367.
     PubMed     Abstract available
     
     
     
175. LIU YC, Zhang X, Yang HN, Zhang L, et al
     Proposals for the delineation of neck clinical target volume for definitive Radiation therapy in patients with oral/ oropharyngeal squamous cell cancer based on lymph node distribution.
     Radiother Oncol. 2024;195:110225.
     PubMed     Abstract available
     
     
     May 2024
176. JOSE BESSO M, Bitto V, Koi L, Wijaya Hadiwikarta W, et al
     Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer.
     Radiother Oncol. 2024 May 30:110348. doi: 10.1016/j.radonc.2024.110348.
     PubMed     Abstract available
     
     
     
177. GEHIN W, Chastagner P, Mansuy L, Bernier-Chastagner V, et al
     Dosimetric analysis of hearing loss after cranial radiation therapy in children: A single-institution study from the french national registry pediart.
     Radiother Oncol. 2024 May 26:110346. doi: 10.1016/j.radonc.2024.110346.
     PubMed     Abstract available
     
     
     
178. SONG J, Yang X, Wu J, Wu Z, et al
     The association analysis between fatigue and body composition loss in patients with nasopharyngeal carcinoma during radiotherapy: An observational longitudinal study.
     Radiother Oncol. 2024 May 24:110340. doi: 10.1016/j.radonc.2024.110340.
     PubMed     Abstract available
     
     
     
179. ZHANG L, Jin S, Wang Y, Zhang Z, et al
     Predict nutrition-related adverse outcomes in head and neck cancer patients undergoing radiotherapy: A systematic review.
     Radiother Oncol. 2024 May 23:110339. doi: 10.1016/j.radonc.2024.110339.
     PubMed     Abstract available
     
     
     
180. NIELSEN CP, Lorenzen EL, Jensen K, Eriksen JG, et al
     Interobserver variation in organs at risk contouring in head and neck cancer according to the DAHANCA guidelines.
     Radiother Oncol. 2024;197:110337.
     PubMed    
     
     
     
181. BOREL C, Sun XS, Coutte A, Bera G, et al
     Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
     Radiother Oncol. 2024;197:110329.
     PubMed     Abstract available
     
     
     
182. ZHANG WW, Guo R
     Response to "Comments on 'Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study'".
     Radiother Oncol. 2024 May 11:110327. doi: 10.1016/j.radonc.2024.110327.
     PubMed    
     
     
     
183. ZHAN ZJ, Huang HY, Xiao YH, Zhao YP, et al
     Anxiety and depression in nasopharyngeal carcinoma patients and network analysis to identify central symptoms: A cross-sectional study from a high-incidence area.
     Radiother Oncol. 2024 May 10:110324. doi: 10.1016/j.radonc.2024.110324.
     PubMed     Abstract available
     
     
     
184. SHEN M, Lin X, Yang C, Zhou Z, et al
     Potential predictive value of IVIM MR for xerostomia in nasopharyngeal carcinoma.
     Radiother Oncol. 2024 May 9:110323. doi: 10.1016/j.radonc.2024.110323.
     PubMed     Abstract available
     
     
     
185. SMITS HJG, Raaijmakers CPJ, de Ridder M, Gouw ZAR, et al
     Improved delineation with diffusion weighted imaging for laryngeal and hypopharyngeal tumors validated with pathology.
     Radiother Oncol. 2024;194:110182.
     PubMed     Abstract available
     
     
     April 2024
186. XU L, Liu S, Yang Y, Shu L, et al
     LINC00313 suppresses autophagy and promotes stemness of nasopharyngeal carcinoma cells through PTBP1/STIM1 axis.
     Radiother Oncol. 2024;196:110310.
     PubMed     Abstract available
     
     
     
187. LIU Y, Ma J, Zeng XY, Zuo ZC, et al
     Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study.
     Radiother Oncol. 2024;196:110311.
     PubMed     Abstract available
     
     
     
188. STARUCH M, Speth MM, Neyer P, Riesterer O, et al
     Radiation-associated changes in saliva composition of head and neck cancer patients: A systematic review.
     Radiother Oncol. 2024 Apr 20:110279. doi: 10.1016/j.radonc.2024.110279.
     PubMed     Abstract available
     
     
     
189. SELENGE BEDUK ESEN C, Nur Can G, Akkus Yildirim B
     Comments on "Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study".
     Radiother Oncol. 2024 Apr 20:110292. doi: 10.1016/j.radonc.2024.110292.
     PubMed    
     
     
     
190. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
     Risk factors associated with the development of osteoradionecrosis (ORN) in Head and Neck cancer patients in Ireland: A 10-year retrospective review.
     Radiother Oncol. 2024 Apr 17:110286. doi: 10.1016/j.radonc.2024.110286.
     PubMed     Abstract available
     
     
     
191. ZHENG Z, Shen Y, Su J, Ji X, et al
     Assessing radiation-induced carotid artery injury using ultrasound in patients with head and neck cancer.
     Radiother Oncol. 2024 Apr 17:110285. doi: 10.1016/j.radonc.2024.110285.
     PubMed     Abstract available
     
     
     
192. CHEN AM, Harris JP, Nabar R, Tjoa T, et al
     Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
     Radiother Oncol. 2024 Apr 16:110278. doi: 10.1016/j.radonc.2024.110278.
     PubMed     Abstract available
     
     
     
193. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
     A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
     Radiother Oncol. 2024 Apr 16:110281. doi: 10.1016/j.radonc.2024.110281.
     PubMed     Abstract available
     
     
     
194. SHUANG H, Feng J, Caineng C, Qifeng J, et al
     Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study.
     Radiother Oncol. 2024 Apr 5:110265. doi: 10.1016/j.radonc.2024.110265.
     PubMed     Abstract available
     
     
     
195. CHOW JCH, Lee J, Lai MMP, Li S, et al
     Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional study.
     Radiother Oncol. 2024;193:110143.
     PubMed     Abstract available
     
     
     March 2024
196. DONG J, Ng WT, Wong CHL, Li JS, et al
     Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis.
     Radiother Oncol. 2024 Mar 25:110258. doi: 10.1016/j.radonc.2024.110258.
     PubMed     Abstract available
     
     
     
197. HUYNH TM, Falk RS, Hellebust TP, Dale E, et al
     Chronic fatigue in long-term survivors of head and neck cancer treated with radiotherapy.
     Radiother Oncol. 2024;195:110231.
     PubMed     Abstract available
     
     
     
198. BERTHOLET J, Mackeprang PH, Loebner HA, Mueller S, et al
     Organs-at-risk dose and normal tissue complication probability with dynamic trajectory radiotherapy (DTRT) for head and neck cancer.
     Radiother Oncol. 2024 Mar 19:110237. doi: 10.1016/j.radonc.2024.110237.
     PubMed     Abstract available
     
     
     
199. BOON CS, Ramkumar S, Boon IS
     Proton beam radiotherapy head and neck cancer study design and endpoints.
     Radiother Oncol. 2024 Mar 16:110234. doi: 10.1016/j.radonc.2024.110234.
     PubMed    
     
     
     
200. KOUTROUMPAKIS E, Mohamed ASR, Chaftari P, Rosenthal DI, et al
     Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study.
     Radiother Oncol. 2024 Mar 9:110220. doi: 10.1016/j.radonc.2024.110220.
     PubMed     Abstract available
     
     
     
201. CHOW JCH, Ho JCS, Man Cheung K, Johnson D, et al
     Neurological complications of modern radiotherapy for head and neck cancer.
     Radiother Oncol. 2024 Mar 2:110200. doi: 10.1016/j.radonc.2024.110200.
     PubMed     Abstract available
     
     
     
202. CARSUZAA F, Chary E, Thariat J, Dufour X, et al
     Obstructive sleep apnea syndrome: A frequent and difficult-to-detect complication of radiotherapy for oropharyngeal cancers.
     Radiother Oncol. 2024;192:110109.
     PubMed     Abstract available
     
     
     
203. ZHANG WW, Lin JY, Wang GY, Huang CL, et al
     Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
     Radiother Oncol. 2024;194:110189.
     PubMed     Abstract available
     
     
     February 2024
204. POPULAIRE P, Defraene G, Haustermans K
     Letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
     Radiother Oncol. 2024 Feb 28:110175. doi: 10.1016/j.radonc.2024.110175.
     PubMed    
     
     
     
205. KOTO M, Ikawa H, Inaniwa T, Imai R, et al
     Dose-averaged LET optimized carbon-ion radiotherapy for head and neck cancers.
     Radiother Oncol. 2024;194:110180.
     PubMed     Abstract available
     
     
     November 2023
206. VERDUIJN GM, Sijtsema ND, van Norden Y, Heemsbergen WD, et al
     Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment.
     Radiother Oncol. 2023;188:109889.
     PubMed     Abstract available
     
     
     
207. LIU Y, Yang B, Chen X, Zhu J, et al
     Efficient segmentation using domain adaptation for MRI-guided and CBCT-guided online adaptive radiotherapy.
     Radiother Oncol. 2023;188:109871.
     PubMed     Abstract available
     
     
     
208. DING X, Cui X, Cui X, Wang S, et al
     Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: A meta-analysis.
     Radiother Oncol. 2023;188:109860.
     PubMed     Abstract available
     
     
     October 2023
209. CHANG CL, Lin KC, Chen WM, Shia BC, et al
     Comparing the Oncologic Outcomes of Proton Therapy and Intensity-Modulated Radiation Therapy for Head and Neck Squamous Cell Carcinoma.
     Radiother Oncol. 2023 Oct 28:109971. doi: 10.1016/j.radonc.2023.109971.
     PubMed     Abstract available
     
     
     September 2023
210. LIU S, Zou Y, Zhong M, Li T, et al
     Prognostic Significance of MRI-Defined Sarcopenia in Patients with Nasopharyngeal Carcinoma: A Propensity Score Matched Analysis of Real-World Data.
     Radiother Oncol. 2023 Sep 5:109904. doi: 10.1016/j.radonc.2023.109904.
     PubMed     Abstract available
     
     
     
211. YAN W, Liu T, He M, Yi J, et al
     Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis.
     Radiother Oncol. 2023 Sep 5:109903. doi: 10.1016/j.radonc.2023.109903.
     PubMed     Abstract available
     
     
     
212. LI D, Yang LN, Lin JY, Wu YZ, et al
     Eosinophil Dynamics During Chemo-Radiotherapy Correlate to Clinical Outcome in Stage ?-?a Nasopharyngeal Carcinoma Patients: Results from A Large Cohort Study.
     Radiother Oncol. 2023 Sep 1:109900. doi: 10.1016/j.radonc.2023.109900.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Otorhinolaryngology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum